Prediagnostic serum levels of inflammatory biomarkers are correlated with future development of lung and esophageal cancer.
Prediagnostic serum levels of inflammatory biomarkers are correlated with future development of lung and esophageal cancer.
复制标题
炎症生物标志物的诊断前血清水平与肺癌和食道癌的未来发展相关。
DOI：
10.1111/cas.12485
复制
发表时间：
2014
期刊：
影响因子：
5.7
通讯作者：
Sikora,AndrewG
中科院分区：
文献类型：
--
作者：
Keeley,BriezeR;Islami,Farhad;Pourshams,Akram;Poustchi,Hossein;Pak,JamieS;Brennan,Paul;Khademi,Hooman;Genden,EricM;Abnet,ChristianC;Dawsey,SanfordM;Boffetta,Paolo;Malekzadeh,Reza;Sikora,AndrewG
本研究在一个高风险前瞻性队列中检验了20种癌症相关炎症生物标志物的诊断前血清水平与头颈癌、食管癌和肺癌的未来发展直接相关的假设。这是一项在戈莱斯坦队列研究（一项正在进行的评估伊朗戈莱斯坦癌症趋势的流行病学项目）入组的受试者中进行的巢式病例对照初探性研究。我们测量了一组20 - 21细胞因子，趋化因子和炎症分子，使用Luminex技术在癌症诊断前2年或更长时间收集的血清样本中，78例呼吸消化道癌症病例和81例对照。采用Wilcoxon秩和检验、比值比、受试者操作特征辨别区和多变量分析对数据进行分析。与对照组相比，未来食管癌和肺癌患者的生物标志物在全球范围内显著升高。几种生物标志物与食管癌未来发展之间的相关性比值比显著，包括白细胞介素-1R α（IL-1 Ra; 35.9）、干扰素α2（IFN-α 2; 34.0）、成纤维细胞生长因子-2（FGF-2; 17.4）和粒细胞/巨噬细胞集落刺激因子（GM-CSF; 17.4）。在未来的肺癌病例中观察到G-CSF（27.7）、GM-CSF（13.3）和肿瘤坏死因子-α（TNF-α; 8.6）的相同模式。相比之下，研究的大多数生物标志物显示与未来头颈部癌症的发展没有显着相关性。这项研究提供了第一个直接证据，表明未来肺癌和食道癌患者在癌症诊断前2年或更长时间内多种炎症生物标志物协同升高。
This study tests the hypothesis that prediagnostic serum levels of 20 cancer‐associated inflammatory biomarkers correlate directly with future development of head and neck, esophageal, and lung cancers in a high‐risk prospective cohort. This is a nested case–control pilot study of subjects enrolled in the Golestan Cohort Study, an ongoing epidemiologic project assessing cancer trends in Golestan, Iran. We measured a panel of 20 21cytokines, chemokines, and inflammatory molecules using Luminex technology in serum samples collected 2 or more years before cancer diagnosis in 78 aerodigestive cancer cases and 81 controls. Data was analyzed using Wilcoxon rank sum test, odds ratios, receiver operating characteristic areas of discrimination, and multivariate analysis. Biomarkers were profoundly and globally elevated in future esophageal and lung cancer patients compared to controls. Odds ratios were significant for association between several biomarkers and future development of esophageal cancer, including interleukin‐1Rα (IL‐1Ra; 35.9), interferon α2 (IFN‐a2; 34.0), fibroblast growth factor‐2 (FGF‐2; 17.4), and granulocyte/macrophage colony‐stimulating factor (GM‐CSF; 17.4). The same pattern was observed among future lung cancer cases for G‐CSF (27.7), GM‐CSF (13.3), and tumor necrosis factor‐α (TNF‐a; 8.6). By contrast, the majority of biomarkers studied showed no significant correlation with future head and neck cancer development. This study provides the first direct evidence that multiple inflammatory biomarkers are coordinately elevated in future lung and esophageal cancer patients 2 or more years before cancer diagnosis.